Exelixis (EXEL) Stock Overview
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
EXEL Community Fair Values
Create NarrativeSee what 174 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Exelixis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$41.03 |
| 52 Week High | US$49.62 |
| 52 Week Low | US$32.38 |
| Beta | 0.42 |
| 1 Month Change | -0.80% |
| 3 Month Change | -5.55% |
| 1 Year Change | 6.43% |
| 3 Year Change | 149.12% |
| 5 Year Change | 85.66% |
| Change since IPO | 170.16% |
Recent News & Updates
Recent updates
Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval
Jan 29With EPS Growth And More, Exelixis (NASDAQ:EXEL) Makes An Interesting Case
May 09
Market Participants Recognise Exelixis, Inc.'s (NASDAQ:EXEL) Earnings
Apr 16Exelixis: Pinning Hopes On Cracking One Of The Toughest Nuts
Mar 13Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza
Jan 09Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
Oct 31
Cabozantinib's Momentum And Tactical Growth Amid Market Challenges Propel Biotech Innovation
Strong commercial performance of the cabozantinib franchise, indicating sustained revenue growth through market penetration and diversification into new indications.Exelixis Comes Up Aces
Aug 08Shareholder Returns
| EXEL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.8% | 1.2% | -0.6% |
| 1Y | 6.4% | 28.8% | 15.5% |
Return vs Industry: EXEL underperformed the US Biotechs industry which returned 28.8% over the past year.
Return vs Market: EXEL underperformed the US Market which returned 15.5% over the past year.
Price Volatility
| EXEL volatility | |
|---|---|
| EXEL Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EXEL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EXEL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,077 | Mike Morrissey | www.exelixis.com |
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
Exelixis, Inc. Fundamentals Summary
| EXEL fundamental statistics | |
|---|---|
| Market cap | US$11.44b |
| Earnings (TTM) | US$782.57m |
| Revenue (TTM) | US$2.32b |
Is EXEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXEL income statement (TTM) | |
|---|---|
| Revenue | US$2.32b |
| Cost of Revenue | US$83.70m |
| Gross Profit | US$2.24b |
| Other Expenses | US$1.45b |
| Earnings | US$782.57m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.01 |
| Gross Margin | 96.39% |
| Net Profit Margin | 33.73% |
| Debt/Equity Ratio | 0% |
How did EXEL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/02 23:57 |
| End of Day Share Price | 2026/03/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Exelixis, Inc. is covered by 41 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Peter Lawson | Barclays |
| Jason Matthew Gerberry | BofA Global Research |